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Abstract
We assessed the contribution of the sweat test, genotyping and nasal potential difference (NPD) in the diagnosis of cystic
fibrosis (CF) in adults with diffuse bronchiectasis (DB). Among 601 adults referred for DB from 1992 to 2001, 46 were
diagnosed with CF. The sweat test was positive in 37 patients and normal or intermediate in nine patients. Two CF mutations
were identified in 18 patients (39%) by screening for 31 mutations and in 36 patients (78%) after complete genetic analysis.
NPD was suggestive of CF in 71% of the patients. The combination of the sweat test and genetic analysis led to the diagnosis of
CF in 45 patients. In the nine patients with normal or intermediate sweat test, the diagnosis was confirmed by screening for 31
mutations in five, by complete genetic screening in three, and by NPD in the remaining patient. Searching for CF should start
with sweat test. If the sweat test is normal or intermediate, screening for 31 mutations may help to diagnose CF. A complete
genetic analysis is indicated when only one mutation is detected andyor when other clinical features, such as obstructive
azoospermia or pancreatic insufficiency, are suggestive of CF. NPD measurement is indicated in controversial cases.
 2003 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.
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1. Introduction
Cystic fibrosis (CF) is the most common serious
genetic disorder among Caucasian populations, with an
incidence of approximately 1:2500 live births and 1:25
asymptomatic carriers w1x. CF is caused by mutations in
the CF transmembrane conductance regulator (CFTR)
gene, which encodes a protein expressed in the apical
membrane of exocrine epithelial cells w2x. The typical
form of CF is diagnosed early in life and is characterized
by recurrent pulmonary infections, pancreatic insuffi-
ciency, elevated chloride concentrations in sweat and
male infertility due to obstructive azoospermia. How-
ever, CF can also be diagnosed at a later age and this
type is often associated with mild lung disease and
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pancreatic sufficiency w3–5x. The diagnosis of CF is
important, as it has prognostic and treatment implica-
tions and may lead to genetic counseling in families.
Thus, patients who are diagnosed with diffuse bronchi-
ectasis (DB) without any causative factors must undergo
complementary investigations to look for CF w6x.
We studied patients who were diagnosed with CF in
adulthood, following the diagnosis of DB. Our aim was
to assess retrospectively the contribution of the sweat
test, genotyping and nasal potential difference (NPD)
measurements, alone or in combination, in the diagnosis
of CF in adults with DB. CF can be diagnosed when
DB is associated with an elevated sweat chloride con-
centration, when two mutations are identified or when
epithelial ion transport is abnormal w7x.
2. Patients and methods
2.1. Patients
All of the adult patients who were referred to the
Pulmonary Department, Cochin Hospital, Paris, with DB
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and who were diagnosed with CF between 1992 and
2001 were eligible for this study. All suspected cases of
bronchiectasis (chronic mucopurulent sputum produc-
tion and recurrent lower respiratory tract infections)
were confirmed by high-resolution computed
tomography.
All the patients with DB without known causative
factor who were referred to our Pulmonary Department
in this period were evaluated for the diagnosis of CF by
clinical assessment, sweat chloride test, analysis of the
CFTR gene and, when possible, NPD measurements.
The aim of our study was to focus on the DB patients
diagnosed as CF and on the reasons for their delayed
diagnosis.
2.2. Clinical assessment
The following characteristics were assessed at time
that CF was diagnosed: age, familial and personal
medical history (particularly digestive problems and
male infertility), pulmonary function tests and sputum
microbiology. Forced vital capacity (FVC) and forced
expiratory volume in one second (FEV1) were expressed
as the percentage of the predicted value. Respiratory
bacterial infections were evaluated using quantitative
sputum cultures. Cultures were considered to be positive
when )10 cfuyml bacteria were present. Pancreatic5
status was determined by the fat content in stool samples
collected over a 72-h period; patients with normal results
(fecal fat -6 gyday) were defined as pancreatic suffi-
cient (PS) and the others were defined as pancreatic
insufficient (PI).
2.3. Sweat chloride test
The pilocarpine iontophoresis test was performed on
both arms with measurements of sweat weight. A min-
imum of 80 mg of sweat was analyzed. Sweat chloride
concentrations were measured by the standard titrimetric
method described by Gibson and Cooke w8x. According
to the guidelines for the performance of the sweat test
for the investigation of CF in the UK (http:yy
www.acb.org.ukyGuidelinesysweat.htm), a sweat chlo-
ride concentration of more than 60 mmol l supportsy1
the diagnosis of CF, intermediate chloride concentration
of 40–60 mmol l is suggestive, but not diagnostic ofy1
CF, a sweat chloride of less than 40 mmol l is normaly1
and there is a low probability of CF. Two sweat tests
were performed for each patient.
2.4. Analysis of the CFTR gene
Genomic DNA was extracted from whole peripheral
blood samples by standard methods. We used an oligon-
ucleotide ligation assay using a commercially available
kit (Cystic Fibrosis Assay, Applied Biosystems, Foster
City, CA, USA) to seek 31 mutations in the CFTR gene
(F508del, I507del, Q943X, V520F, 1717y1G™A,
G542X, G551D, R553X, R560T, S549R, S549 N,
3849q10kbC™T, 3849q4A™G, R1162X, 3659delC,
W1282X, 3905insT, 621q1G™T, R117H, Y122X,
711q1G™T, 1078delT, R347P, R347H, R334 W,
A455E, N1303K, G85E, 1898q1G™A, 2183AA™G,
2789q5G™A) which allowed to detect 82% of the CF
alleles in France. For totally or partially uncharacterized
samples, all 27 exons and flanking regions of the CFTR
gene were screened for mutations and polymorphisms
by denaturing gradient gel electrophoresis (DGGE) on
genomic DNA amplified by the polymerase chain reac-
tion w9,10x. Each PCR product with an abnormal DGGE
pattern was directly sequenced with the dye deoxy chain
terminator method on an ABI 377 sequencer in order to
identify the mutation or the sequence variation that
caused abnormal migration. In addition, the IVS8(T)n
acceptor site polymorphism was analyzed by nested
PCR and polyacrylamide gel electrophoresis w11x.
2.5. Nasal potential difference measurement
Nasal potential difference was measured according to
the method described by Alton et al. w12x in patients
without acute upper airway infections. The exploring
electrode consisted of a Foley catheter filled with 1:1
vyv mixture of electrocardiographic (ECG) electrode
cream and Ringer’s lactate. The perfusion rate was 1.5
ml min . The reference electrode consisted of a silveryy1
silver chloride electrode, which was positioned on the
patient’s forearm after adequate skin abrasion. Both
electrodes were connected to a high impedance voltme-
ter, the exploring electrode connected via the silvery
silver chloride electrode. The offset of the electrodes
was first measured and the recorded values were cor-
rected accordingly. The Foley catheter was passed along
the bottom of the nose and slowly withdrawn to detect
the point of maximal potential difference, which had to
be stable for at least 15 s. The highest value was noted.
The mean ("S.D.) nasal potential difference for the
normal population used as a reference in our laboratory,
expressed in absolute values, was 20.5"5.9 mV and
values )30 mV were considered to be abnormal.
2.6. Diagnosis of cystic fibrosis
In patients with DB, which is a characteristic clinical
feature of CF, CF was diagnosed when one of the
laboratory tests (the sweat test or the NPD measure-
ment) was positive or when two CF mutations were
identified w7x.
3. Results
3.1. Clinical characteristics of the CF patients
Over the 10-year study period, 601 adults with DB
attended our pulmonary department. Among them, 46
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Table 1
Clinical features of the patients at the time of CF diagnosis
Patient Sex Age FVC FEV1 Sputum Pancreatic Male Family
(year) (% pred.) (% pred.) culture status sterility history
Patients with positive sweat test
1 M 34 90 83 SA PI* yes*
2 F 31 76 52 PA PI
3 F 35 62 29 PA PI
4 F 18 67 39 SA PI
5 F 35 77 64 PA PS
6 F 27 42 32 SA PS
7 F 29 90 62 PA PS
8 M 28 91 77 SA PI ?
9 F 34 35 32 PA PI
10 M 21 101 93 SA PS ? yes
11 M 25 77 53 SA, PA, HI PS ? yes
12 F 34 93 87 SA PS
13 F 34 58 33 PA PS yes
14 F 45 102 105 SA PS
15 F 27 101 95 HI PI*
16 M 26 73 44 SA PI yes
17 M 24 101 96 NA PS ?
18 M 19 94 73 SA PI ?
19 F 30 72 51 HI PI
20 M 18 43 21 PA PS yes
21 M 30 82 72 SA PS ?
22 M 51 79 56 SA PS yes*
23 M 28 115 78 SA PS yes*
24 F 25 40 27 PA PS
25 M 34 88 63 PA PS yes*
26 M 30 81 82 HI PS yes
27 M 39 51 27 SA PS yes*
28 F 28 45 31 SA, PA PS
29 M 29 95 94 SA PS yes*
30 F 24 67 57 SA PS yes
31 M 27 70 50 SA PI yes yes
32 F 41 72 70 PA PS yes
33 M 45 74 66 PA PS yes* yes
34 M 19 60 33 SA PS yes
35 F 31 43 27 PA PS yes
36 M 26 45 36 SA PS yes*
37 F 24 66 30 PA PS
Patients with normal or intermediate sweat test
38 M 54 81 45 SA PS ?
39 F 25 107 107 normal PS
40 F 32 53 25 PA PS yes
41 M 20 78 73 PA PI no
42 F 30 75 59 PA PS
43 F 33 83 78 PA PS yes
44 M 56 40 30 PA PS yes*
45 M 37 43 33 Klebsiella PS yes*
46 M 42 73 60 SA, HI PS yes* yes
Mean"S.D. 31"9 73"21 56"25
Msmale; Fsfemale; SAsS. aureus; HIsH. influenzae; PAsP. aeruginosa; PIspancreatic insufficient; PSspancreatic sufficient; *: known
before diagnosis of bronchiectasis; NA: not available.
patients (7.6%), 24 males and 22 females, were diag-
nosed as CF and included in the study. Their clinical
features at diagnosis of CF are given in Table 1. The
mean age of the patients was 31 years (range, 18–56
years). In all cases except three, the pulmonary function
tests showed obstructive pulmonary disease. The mean
FVC was 73% of the predicted value and the mean
FEV1 was 56% of the predicted value. It is noticeable
that 16 out of the 46 patients were presenting with a
severe lung disease (FEV1-40%) at the time of diag-
nosis, although their respiratory symptoms had begun
early in childhood, and were considered as asthma,
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chronic bronchitis or DB of unknown origin; four of
them (3, 13, 24 and 40) had a previous sweat test
considered as negative, whereas the sweat test had not
been done during childhood in the 12 others.
Microbiological studies revealed the presence of
Staphylococcus aureus in 22 patients (48%), Pseudo-
monas aeruginosa in 20 patients (43%) and Haemophi-
lus influenzae in four patients. Only 12 patients (26%)
were pancreatic insufficient, but most of these PI patients
did not complain of digestive symptoms at the time of
the initial evaluation. Steatorrhea was diagnosed during
childhood in patients 1 and 15. These patients were
treated with pancreatic enzymes, but were not diagnosed
as CF until the onset of the respiratory symptoms
(patient 1 had had a previous sweat test, which was
negative). Only three other patients (4, 8, and 19)
complained of abdominal discomfort and diarrhea at the
time of the initial assessment. Eleven male patients
knew that they had a fertility problem at the time of the
initial evaluation and had received medical assistance
for procreation. All of the men who agreed to be tested,
except patient  41, had obstructive azoospermia. Final-
ly, 11 of the patients had a family history of CF: patients
10 and 11, 13 and 40, 30 and 31, 32 and 33, 35 and
46 were siblings.
3.2. Sweat test
Thirty-seven of the patients had sweat chloride con-
centrations of G60 mmol l (80%) (Tables 2 and 3).y1
A single CFTR mutation was identified in nine of these
patients and thus the sweat test was essential for the
diagnosis of CF. The sweat test was normal or interme-
diate in nine of the 46 patients diagnosed as CF (20%).
False positive sweat tests were initially registered in two
patients with DB, but the diagnosis of CF was finally
ruled out by normal subsequent sweat test, normal NPD
and the absence of CFTR mutations.
3.3. Genotype
The results of genetic analysis are summarized in
Table 2. The efficacy of the genetic analysis for the
diagnosis of CF depended on the strategy used (Table
4). Only three patients were homozygous for the
F508del mutation and 31 patients had at least one copy
of this mutation (67%). Screening for nine mutations,
as done by Pasteur et al. to investigate patients with
bronchiectasis w6x, would have detected two mutations
in six patients (13%) and at least one mutation in 36
patients (78%). Screening for 31 mutations identified
two mutations in 18 patients (39%) and at least one
CFTR mutation in 43 patients (93%). This method
identified mutations in all but three patients. Finally,
complete analysis of the CFTR gene identified two
mutations in 36 patients (78%) and at least one mutation
in all 46 patients. The 5T allele was identified in only
one patient (26).
Genotyping confirmed the diagnosis of CF in all but
one of the nine patients with a normal sweat test: in
patients 38–42, the screening for 31 mutations con-
firmed the diagnosis, whereas in patients 43–45, two
CFTR mutations were identified after screening the
entire CFTR gene. The results of the sweat test and the
genotyping could not confirm the diagnosis of CF in
one patient (46).
The combination of the sweat test and genotyping
was more sensitive than any of the tests alone, leading
to the diagnosis of CF in 42 patients (91%) when
screening for 31 mutations and in 45 patients (98%)
after complete screening of the CFTR gene (Table 3).
3.4. Nasal potential difference
NPD was G30 mV in 27 patients out of 38 (71%).
Five of the nine patients with normal NPD had a normal
sweat test and diagnosis was made by the identification
of two CFTR mutations (by the screening for 31
mutations in patients 39, 41 and 42 and by complete
screening in patients 44 and 45). NPD was essential
for diagnosis in one patient (46) with a borderline
sweat test and only one identified mutation.
4. Discussion
In this study, we have reviewed the results of the
laboratory tests used for the diagnosis of CF in 46
patients in whom CF was diagnosed in adulthood as a
result of investigation of DB. We aimed to assess the
contribution of sweat testing, genotyping and NPD
measurements, alone or in combination, in the diagnosis
of CF in adult patients with bronchiectasis.
CF is most often diagnosed at a late age because of
recurrent pulmonary infections and occasionally because
of gastrointestinal symptoms. DB is a common cause of
diagnosis of atypical CF in adults and the incidence of
CF was 7.6% among our total cohort of patients with
DB. In the study by Pasteur et al. w6x, the incidence of
CF in 150 adults with bronchiectasis was 2.7%, based
on elevated sweat chloride levels; nevertheless, the
actual incidence of CF might have been underestimated
in this study as CF with a normal sweat test and rare
mutations could not be identified. Several studies have
found a high frequency of CFTR mutations in DB w13–
15x. Our study underlined the undoubtedly presence of
CF patients among DB subjects, without the correct
diagnosis until a severe lung disease is present. An early
diagnosis of CF is a prerequisite for an adequate thera-
peutic approach which leads to a better prognosis of the
disease.
A high proportion of the CF patients diagnosed in
adulthood are pancreatic sufficient and have mild muta-
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Table 2
Results of genotyping, sweat test and nasal potential difference test
Patient Genotype Sweat test, Basal nasal potential
chloride difference
(mmol l )y1 (mV)
Patients with positive sweat test
1 F508delyF508del 120 31
2 F508delyF508del 110 26
3 F508delyF508del 130 29
4 F508delyG551D 123 49
5 F508delyA455E 115 29
6 F508delyA455E 110 40
7 F508delyA455E 106 35
8 F508delyW1282X 100 48
9 F508dely2789H5G™A 142 52
10 2183AA™Gy2789H5G™A 72 NA
11 2183AA™Gy2789H5G™A 105 NA
12 2183AA™Gy2789H5G™A 70 43
13 G542Xy3849H10kbC™T 70 38
14 F508delyL206W 104 30
15 F508delyW846X 100 23
16 F508dely2347delG 114 NA
17 F508delyQ237E 69 39
18 F508delyG1061R 125 35
19 F508delyQ1313X 102 NA
20 F508dely4382delA 134 32
21 F508delyH1054D 100 51
22 F508delyD1152H 89 39
23 F508delyG27E 120 35
24 F508delyD192N 119 31
25 F508dely3272y26A™G 104 45
26 F508dely5T 60 22
27 1717I1G™Ay3272y26A™G 106 28
28 W361Ry297y3C™T 100 NA
29 F508delyy 67 47
30 F508delyy 102 44
31 F508delyy 75 42
32 F508delyy 112 43
33 F508delyy 82 45
34 F508delyy 97 NA
35 G542Xyy 86 35
36 G85Eyy 115 NA
37 R600Gyy 108 36
Patients with normal or intermediate sweat test
38 F508delyR117H 38 52
39 F508delyR117H 58 22
40 G542Xy3849H10kbC™T 30 40
41 G542Xy3849H10kbC™T 52 19
42 R347Py3849H10kbC™T 43 27
43 F508delyR1070W 53 NA
44 I507delyS1235R 53 20
45 R1070QyD1152H 56 29
46 G542Xyy 59 48
Mean"S.D. 92"27 35"9
NA: not available.
CF mutations detected by screening for 31 mutations are indicated in bold type.
tions w4,16x. Although it is difficult to establish relation-
ships between genotype and pulmonary phenotype w17x,
mild CFTR mutations are associated with pancreatic
sufficiency w18x and the rate of decline of pulmonary
function is slower in pancreatic sufficient patients w19x.
Classical CF can easily be diagnosed or ruled out by
the sweat test. However, atypical CF, including patients
who are diagnosed at a late age due to exclusively or
predominantly pulmonary symptoms, may necessitate
more extensive testing w20x. The consensus opinion is
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Table 3
Sensitivity of the sweat test and genotyping for the diagnosis of cystic fibrosis
Positive diagnosis of CF
Number of patients (percentage)
Sweat test (sweat chloride)60 mmol l )y1 37 (80%)
Molecular analysis:
-screening for 31 mutations 18 (39%)
-complete screening 36 (78%)
Combination of sweat test and molecular analysis:
-sweat testqscreening for 31 mutations 42 (91%)
-sweat testqcomplete screening 45 (98%)
Table 4
Efficacy of the CFTR genetic analysis according to the screening method used
Identified mutations Two mutations At least one mutation No mutations
Screening for F508del
Number of patients (%) 3 (7%) 31 (67%) 15 (33%)
Screening for nine mutations*
Number of patients (%) 6 (13%) 36 (78%) 10 (22%)
Screening for 31 mutations**
Number of patients (%) 18 (39%) 43 (93%) 3 (7%)
Complete screening
Number of patients (%) 36 (78%) 46 (100%) 0
Nine mutations: F508del, I507del, G542X, G551D, R553X, 621q1G™T, G85E, R117H, N1303K.*
31 mutations: F508del, I507del, Q493X, V520F, 1717y1G™A, G542X, G551D, R553X, R560T, S549R, S549 N, 3849q10kbC™T, 3849q**
4A™G, R1162X, 3659delC, W1282X, 3905insT, 621q1G™T, R117H, Y122X, 711q1G™T, 1078delT, R347P, R347H, R334 W, A455E,
N1303K, G85E, 1898q1G™A, 2183AA™G, 2789q5G™A.
that the laboratory criteria for the diagnosis of CF should
be expanded to include identification of CFTR mutations
and abnormal bioelectrical properties of the nasal epi-
thelium, in addition to the sweat test w7x. CF can be
diagnosed on the basis of one characteristic phenotypic
feature, such as DB, associated with an elevated sweat
chloride concentration or the identification of two CF
mutations or the demonstration of abnormal epithelial
ion transport w7x. In our patients, the occurrence of
digestive symptoms andyor male sterility was a good
clinical indicator of CF. In 1982, Stern et al. w21x
recognized that patients with isolated characteristics of
CF, but whose sweat chloride concentrations were not
clearly raised, could pose diagnostic difficulties. They
noticed that azoospermia could be central in diagnosis
and proposed that CF should be diagnosed in patients
with at least two major criteria, including the chronic
obstructive pulmonary disease with Pseudomonas air-
way infection and unexplained obstructive azoospermia.
The sweat test, which measures sweat chloride con-
centrations by pilocarpine iontophoresis, has served as
the main diagnosis test for CF over 40 years w8x.
However, it is now clear that some CF mutations are
associated with normal sweat chloride values, as
described for the 3849q10kbC™T w22x and G551S
mutations w23x. In these cases, CF can be diagnosed
based on identification of two known mutations. Nine
of our patients had a negative sweat test, but this high
proportion can be explained by the fact that mild
mutations are more frequent in patients diagnosed in
adulthood w24x. The CFTR genetic analysis confirmed
the diagnosis by identifying two CF mutations in eight
of these patients, three of whom carried the 3849q
10kbC™T mutation. Four of the 32 DB patients
described by Girodon et al. w14x had negative sweat test
and were compound heterozygous for the CFTR gene;
two of these patients carried the 3849q10kbC™T
mutation. Another study focused on 24 children with
various pulmonary diseases and intermediate sweat chlo-
ride values (between 40 and 60 mmol l ) w25x; knowny1
CFTR mutations were found in 12 of these patients and
three of the patients were homozygous or compound
heterozygous (F508delyF508del, F508dely3849q
10kbC)T, S1235RyG551D). The S1235R mutation
was also found in one of our patients who had a
negative sweat test, but chronic bronchial colonization
with P. aeruginosa and obstructive azoospermia. Mon-
aghan et al. w26x suggested that S1235R is pathogenic
when combined with a second CF mutation, although
phenotypic manifestations appear to be variable.
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We identified at least one CFTR mutation in all 46
patients studied and two mutations in 78% of them;
three of the patients were F508del homozygous and 33
were compound heterozygous. Screening for the 31 most
common mutations in the CFTR gene allowed us to
detect rapidly at least one mutation in 93% of the
patients and two mutations in 39%. If we had limited
the screening to nine mutations, as proposed by Pasteur
et al. w6x, these values would have fallen to 78% and
13%, respectively. We detected an IVS8-5T mutation in
only one patient, who was diagnosed with CF because
of respiratory symptoms, a bilateral absence of the vas
deferens was found afterwards. Many of our patients
had at least one mild mutation, explaining the high
frequency of pancreatic sufficiency. The F508del muta-
tion was found in 31 patients and the G542X mutation
was found in five patients. The next most frequent
mutations were the 2183AA™G, 3849q10kbC™T,
3272y26A™G, A455E and 2789q5G™A mutations,
which were all found in at least three patients. The
3849q10kbC™T, 3272y26A)G, A455E and 2789q
5G™A mutations belong to the class V of CFTR
mutations, which result in residual levels of CFTR
transcripts and protein w17,24x. The A455E missense
mutation is associated with mild lung disease w27x,
whereas the 3272y26A™G w28x, 2789q5G™A w29x
and 3849q10kbC™T w22x mutations are associated
with a milder CF phenotype.
In these CF patients diagnosed in adulthood, the
combination of sweat test and genetic analysis was
necessary to ensure that no cases of CF were missed:
the sweat test alone failed to diagnose CF in 20% of
the patients and the genetic analysis alone failed to
diagnose 22% of the patients, whereas the combination
of the two tests led to the diagnosis of CF in all of the
patients but one. In this patient (46), who had a
borderline sweat test and only one identified CFTR
mutation, raised NPD values confirmed the diagnosis of
CF. Pathologically high NPD values have only been
found in patients with CF and not in patients with any
other lung disease with related clinical manifestations
such as a1-antitrypsin deficiency, immotile cilia syn-
drome or congenital bronchiectasis w30x.
We conclude that adults with DB of unknown etiology
should undergo a sweat test, which remains the reference
test for the diagnosis of CF and is cheap. Nevertheless,
a normal or borderline sweat test does not exclude the
diagnosis of CF in adults with CF like diseases and
genotyping should be carried out, screening for the 31
most frequent CFTR mutations. If only one mutation is
detected andyor other suggestive clinical features are
present, such as obstructive azoospermia or pancreatic
insufficiency, the whole CFTR gene should be screened
for mutations. In controversial cases, NPD measurement
is useful to demonstrate abnormal CFTR function, even
in patients with normal or borderline sweat tests w31x.
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